Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Sci Rep. 2022 May 4;12(1):7297. doi: 10.1038/s41598-022-11064-4.
One-step nucleic acid amplification (OSNA) is a rapid intraoperative molecular detection technique for sentinel node assessment via the quantitative measurement of target cytokeratin 19 (CK19) mRNA to determine the presence of metastasis. It has been validated in breast cancer but its application in lung cancer has not been adequately investigated. 214 LNs from 105 patients with 100 primary lung cancers, 2 occult primary lung tumors, and 3 metastatic lung tumors, who underwent surgical lung resection with LN dissection between February 2018 and January 2020, were assessed. Resected LNs were divided into two parts: one was snap-frozen for OSNA and the other underwent rapidly frozen histological examination. Intraoperatively collected LNs were evaluated by OSNA using loop-mediated isothermal amplification and compared with intraoperative pathological diagnosis as a control. Among 214 LNs, 14 were detected as positive by OSNA, and 11 were positive by both OSNA and intraoperative pathological diagnosis. The sensitivity and specificity of OSNA was 84.6% and 98.5%, respectively. The results of 5 of 214 LNs were discordant, and the remainder all matched (11 positive and 198 negative) with a concordance rate of 97.7%. Although the analysis of public mRNA expression data from cBioPortal showed that CK19 expression varies greatly depending on the cancer type and histological subtype, the results of the five cases, except for primary lung cancer, were consistent. OSNA provides sufficient diagnostic accuracy and speed and can be applied to the intraoperative diagnosis of LN metastasis for non-small cell lung cancer.
一步法核酸扩增(OSNA)是一种快速的术中分子检测技术,通过定量测量目标细胞角蛋白 19(CK19)mRNA 来评估前哨淋巴结,以确定是否存在转移。该技术已在乳腺癌中得到验证,但在肺癌中的应用尚未得到充分研究。2018 年 2 月至 2020 年 1 月期间,对 105 例 100 例原发性肺癌、2 例隐匿性原发性肺癌和 3 例转移性肺癌患者进行了手术肺切除和淋巴结清扫术,共评估了 214 个淋巴结。切除的淋巴结分为两部分:一部分用于 OSNA 检测,另一部分用于快速冷冻组织学检查。术中收集的淋巴结通过环介导等温扩增(LAMP)进行 OSNA 评估,并与术中病理诊断作为对照进行比较。在 214 个淋巴结中,有 14 个通过 OSNA 检测呈阳性,11 个通过 OSNA 和术中病理诊断均呈阳性。OSNA 的灵敏度和特异性分别为 84.6%和 98.5%。214 个淋巴结中有 5 个结果不一致,其余均与(11 个阳性和 198 个阴性)相匹配,一致性率为 97.7%。虽然 cBioPortal 公共 mRNA 表达数据的分析表明,CK19 的表达因癌症类型和组织学亚型而异,但除了原发性肺癌外,其余 5 例的结果是一致的。OSNA 提供了足够的诊断准确性和速度,可以应用于非小细胞肺癌的术中淋巴结转移诊断。